Intravitreal ranibizumab (Lucentis) for choroidal neovascularization associated with Stargardt’s disease

  • Giuseppe Querques
  • Maria Cecilia Angulo Bocco
  • Gisele Soubrane
  • Eric H Souied
Case Report



To describe a young patient with choroidal neovascularization, associated with Stargardt’s disease, who underwent treatment with intravitreal ranibizumab.


A 26-year-old man with a diagnosis of Stargard’s disease presented at our department for sudden decreased vison in his right eye (20/800). Upon a complete oplthamologic examination, including fluorescein angiography (FA), indocyanine green angiography (ICGA) and optical coherence tomography (OCT), the patient was diagnosed with subfoveal CNV of the right eye. Owing to the subfoveal localization of the CNV, intravitreal ranibizumab injection was performed on this young patient.


Three months after the last intravitreal injection of ranibizumab, fundus biomicroscopy, FA, ICGA and OCT revealed the CNV closure and total resolution of the associated cistoid macular edema and serous retinal detachment, with no recurrence and no complication from the intravitreal injection of ranibizumab. Visual acuity improved only to 20/400.


Intravitreal ranibizumab injection seems to induce total regression of CNV complicating Stargardt’s disease. Further investigations are required to confirm our results.


Intravitreal ranibizumab Lucentis Macular dystrophy Stargardt’s disease. 


  1. 1.
    Stargardt K (1909) Ueber familiare progressive Degeneration in der Makulagegend des Auges. Albrecht Von Graefes Arch Ophthalmol 71:534–50Google Scholar
  2. 2.
    Cibis GW, Morey M, Karris DJ (1980) Dominantly inherited macular dystrophy with flecks (Stargardt). Arch Ophthalmol 98:1785PubMedGoogle Scholar
  3. 3.
    Merlin S, Landau J (1970) Abnormal findings in relatives of patients with juvenile hereditary macular degeneration (Stargardt’s disease). Ophthalmologica 161:1CrossRefGoogle Scholar
  4. 4.
    Allikmets R, Singh N, Sun H et al (1997) A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is mutated in recessive Stargardt macular dystrophy. Nat Genet 15:236–46PubMedCrossRefGoogle Scholar
  5. 5.
    Cremers FP, van de Pol DJ, van Driel M et al (1998) Autosomal recessive retinitis pigmentosa and cone-rod dystrophy caused by splice site mutations in the Stargardt’s disease gene ABCR. Hum Mol Genet 7:355–62PubMedCrossRefGoogle Scholar
  6. 6.
    Rozet JM, Gerber S, Souied E et al (1998) Spectrum of ABCR gene mutations in autosomal recessive macular dystrophies. Eur J Hum Genet 6:291–5PubMedCrossRefGoogle Scholar
  7. 7.
    Klein R, Lewis RA, Meyers SM, Myers FL (1978) Subretinal neovascularization associated with fundus flavimaculatus. Arch Ophthalmol 96:2054–2057PubMedGoogle Scholar
  8. 8.
    Rosenfeld PJ, Brown DM, Heier JS et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431PubMedCrossRefGoogle Scholar
  9. 9.
    Brown DM, Kaiser PK, Michels M et al (2006) Ranibizumab vs verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432–1444PubMedCrossRefGoogle Scholar
  10. 10.
    Souied EH, Pawlak D, Algan M et al (2005) Photodynamic therapy for choroidal neovascularization on late-onset fundus flavimaculatus. Am J Ophthalmol 140:312–4PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Giuseppe Querques
    • 1
    • 2
  • Maria Cecilia Angulo Bocco
    • 2
  • Gisele Soubrane
    • 2
  • Eric H Souied
    • 2
  1. 1.Department of Ophthalmology, Ospedali RiunitiUniversity of FoggiaFoggiaItaly
  2. 2.Department of OphthalmologyUniversity of Paris XII, Centre Hospitalier Intercommunal de CreteilCreteilFrance

Personalised recommendations